Christophe Arbet-Engels - 13 Feb 2024 Form 4/A Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Medical Officer
Issuer ticker: XFOR
Reported as of: 13 Feb 2024
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 28 Feb 2024, 17:52:37 UTC
Original report date: 16 Feb 2024
Prior SEC filing: 05 Sep 2023
Next SEC filing: 27 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Adam S. Mostafa, attorney-in-fact

Key filing fact

Christophe Arbet-Engels filed Form 4/A for X4 Pharmaceuticals, Inc (XFOR) on 28 Feb 2024.

Key facts

This page summarizes Christophe Arbet-Engels's Form 4/A filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Feb 2024, 17:52.

Change

Previous filing in this sequence was filed on 05 Sep 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XFOR transaction Derivative

Stock Appreciation Right

Award

Transaction value: $0
Shares: +180,816
Change %
Price: $0.000000
Shares after: 180,816
Date: 13 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 180,816
Exercise price: $0.9210
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This Form 4 amendment is being filed to correct the number of stock appreciation rights awarded to the Reporting Person on February 13, 2024. The original Form 4 filed on February 16, 2024 inadvertently reported the number of stock appreciation rights awarded as 475,831 due to an administrative error.

Footnote F2

The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.